A detailed history of Kornitzer Capital Management Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Kornitzer Capital Management Inc holds 370,853 shares of GILD stock, worth $34.8 Million. This represents 0.6% of its overall portfolio holdings.

Number of Shares
370,853
Previous 370,878 0.01%
Holding current value
$34.8 Million
Previous $25.4 Million 22.16%
% of portfolio
0.6%
Previous 0.5%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$66.59 - $83.99 $1,664 - $2,099
-25 Reduced 0.01%
370,853 $31.1 Million
Q2 2024

Aug 02, 2024

SELL
$63.15 - $72.88 $252,915 - $291,884
-4,005 Reduced 1.07%
370,878 $25.4 Million
Q1 2024

May 01, 2024

SELL
$71.58 - $87.29 $31,638 - $38,582
-442 Reduced 0.12%
374,883 $27.5 Million
Q4 2023

Jan 31, 2024

SELL
$73.27 - $83.09 $85,725 - $97,215
-1,170 Reduced 0.31%
375,325 $30.4 Million
Q3 2023

Oct 31, 2023

SELL
$73.94 - $80.67 $54,937 - $59,937
-743 Reduced 0.2%
376,495 $28.2 Million
Q2 2023

Aug 01, 2023

SELL
$76.01 - $86.7 $38,005 - $43,350
-500 Reduced 0.13%
377,238 $29.1 Million
Q1 2023

May 09, 2023

SELL
$77.31 - $88.08 $109,239 - $124,457
-1,413 Reduced 0.37%
377,738 $31.3 Million
Q4 2022

Feb 02, 2023

SELL
$62.32 - $89.47 $143,647 - $206,228
-2,305 Reduced 0.6%
379,151 $32.6 Million
Q3 2022

Nov 03, 2022

BUY
$59.54 - $68.01 $112,709 - $128,742
1,893 Added 0.5%
381,456 $23.5 Million
Q2 2022

Aug 03, 2022

BUY
$57.72 - $65.01 $1.78 Million - $2.01 Million
30,915 Added 8.87%
379,563 $23.5 Million
Q1 2022

Apr 27, 2022

BUY
$57.92 - $72.58 $181,057 - $226,885
3,126 Added 0.9%
348,648 $20.7 Million
Q4 2021

Feb 01, 2022

SELL
$64.88 - $73.64 $219,943 - $249,639
-3,390 Reduced 0.97%
345,522 $25.1 Million
Q3 2021

Nov 03, 2021

BUY
$67.69 - $73.03 $80,686 - $87,051
1,192 Added 0.34%
348,912 $24.4 Million
Q2 2021

Jul 30, 2021

BUY
$63.47 - $69.35 $978,072 - $1.07 Million
15,410 Added 4.64%
347,720 $23.9 Million
Q1 2021

Apr 30, 2021

BUY
$60.0 - $68.46 $2.14 Million - $2.44 Million
35,645 Added 12.02%
332,310 $21.5 Million
Q4 2020

Jan 29, 2021

BUY
$56.65 - $64.55 $1.79 Million - $2.04 Million
31,592 Added 11.92%
296,665 $17.3 Million
Q3 2020

Oct 30, 2020

BUY
$62.1 - $78.08 $1.72 Million - $2.16 Million
27,675 Added 11.66%
265,073 $16.8 Million
Q2 2020

Aug 03, 2020

BUY
$72.34 - $84.0 $2.91 Million - $3.38 Million
40,213 Added 20.39%
237,398 $18.3 Million
Q1 2020

Apr 30, 2020

BUY
$62.63 - $80.22 $267,430 - $342,539
4,270 Added 2.21%
197,185 $14.7 Million
Q4 2019

Jan 31, 2020

BUY
$61.62 - $67.78 $59,463 - $65,407
965 Added 0.5%
192,915 $12.5 Million
Q3 2019

Nov 04, 2019

BUY
$62.51 - $69.0 $361,307 - $398,820
5,780 Added 3.1%
191,950 $12.2 Million
Q2 2019

Jul 31, 2019

SELL
$61.87 - $69.38 $149,725 - $167,899
-2,420 Reduced 1.28%
186,170 $12.6 Million
Q1 2019

May 01, 2019

BUY
$62.53 - $70.05 $885,737 - $992,258
14,165 Added 8.12%
188,590 $12.3 Million
Q4 2018

Jan 31, 2019

BUY
$60.54 - $79.0 $16,043 - $20,935
265 Added 0.15%
174,425 $10.9 Million
Q3 2018

Nov 13, 2018

BUY
$71.28 - $78.92 $11,404 - $12,627
160 Added 0.09%
174,160 $13.4 Million
Q2 2018

Aug 02, 2018

BUY
$64.88 - $75.68 $46,064 - $53,732
710 Added 0.41%
174,000 $12.3 Million
Q1 2018

Apr 30, 2018

SELL
$72.84 - $88.8 $98,698 - $120,324
-1,355 Reduced 0.78%
173,290 $13.1 Million
Q4 2017

Jan 31, 2018

SELL
$71.15 - $83.52 $4.05 Million - $4.76 Million
-56,979 Reduced 24.6%
174,645 $12.5 Million
Q3 2017

Oct 31, 2017

BUY
$72.11 - $85.47 $16.7 Million - $19.8 Million
231,624
231,624 $18.8 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $118B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Kornitzer Capital Management Inc Portfolio

Follow Kornitzer Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kornitzer Capital Management Inc , based on Form 13F filings with the SEC.

News

Stay updated on Kornitzer Capital Management Inc with notifications on news.